Eli Lilly-backed ReadCoor took its total funding to $50m and will use the funding to commercialise its gene sequencing technology.

ReadCoor, a US-based gene sequencing technology developer backed by pharmaceutical firm Eli Lilly, has secured $27m in series B funding. The cash was supplied by Singaporean government-owned investment vehicle Pavilion Capital, investment firm Decheng Capital and Hansjörg Wyss, founder of Harvard’s Wyss Institute for Biologically Inspired Engineering, in addition to unnamed existing backers. Founded in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.